Needham & Company LLC Increases Esperion Therapeutics, Inc. (NASDAQ:ESPR) Price Target to $72.00
Esperion Therapeutics, Inc. (NASDAQ:ESPR) had its target price upped by investment analysts at Needham & Company LLC from $58.00 to $72.00 in a research report issued to clients and investors on Tuesday, The Fly reports. The firm presently has a “positive” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target suggests a potential upside of 59.40% from the stock’s current price.
A number of other analysts have also recently weighed in on ESPR. Zacks Investment Research cut shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, May 1st. ValuEngine upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Deutsche Bank AG started coverage on shares of Esperion Therapeutics in a report on Friday, June 23rd. They set a “buy” rating and a $48.00 target price for the company. Finally, BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, June 25th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $39.16.
Shares of Esperion Therapeutics (ESPR) traded up 26.39% on Tuesday, hitting $57.09. The company had a trading volume of 2,891,225 shares. The company has a 50-day moving average of $44.47 and a 200 day moving average of $33.65. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $57.15. The stock’s market cap is $1.29 billion.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Neuberger Berman Group LLC purchased a new position in shares of Esperion Therapeutics during the second quarter valued at approximately $764,000. Bank of New York Mellon Corp raised its stake in Esperion Therapeutics by 9.8% in the second quarter. Bank of New York Mellon Corp now owns 114,853 shares of the biopharmaceutical company’s stock valued at $5,315,000 after buying an additional 10,250 shares in the last quarter. SG Americas Securities LLC raised its stake in Esperion Therapeutics by 74.5% in the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 2,991 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in Esperion Therapeutics during the second quarter valued at about $509,000. Finally, Schwab Charles Investment Management Inc. raised its stake in Esperion Therapeutics by 23.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 68,275 shares of the biopharmaceutical company’s stock valued at $3,160,000 after buying an additional 13,146 shares in the last quarter. Institutional investors and hedge funds own 85.20% of the company’s stock.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.